The G-protein-coupled seven-transmembrane receptor superfamily includes the oxytocin receptor. Its primary physiological function is to control the smooth muscle contraction of the uterus during labor and the release of milk from the lactating breast. The binding of oxytocin and a related nonapeptide, vasopressin, causes the oxytocin receptors to become active. Multiple neuroendocrine and cognitive processes are regulated by the oxytocin receptor by Gi or Gq protein-mediated signaling cascades.
A nonapeptide belonging to the family of neurohypophyseal proteins, oxytocin specifically binds to the oxytocin receptor to trigger numerous central and peripheral physiological reactions. Oxytocin is a paracrine and/or autocrine mediator of a variety of biological effects in vivo. The interactions with G-protein-coupled oxytocin/vasopressin receptors, which, through Gq and Gi, stimulate phospholipase C-mediated hydrolysis of phosphoinositides, are the main mechanism by which these effects are exerted.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V74430 | (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin | 77327-45-8 | (d(CH2)51,Tyr(Me)2,Orn8)-Oxytocin (OVT) is an oxytocin receptor blocker (antagonist). |
|
V74428 | (d(CH2)51,Tyr(Me)2,Thr4,Orn8,des-Gly-NH29)-Vasotocin | 115499-13-3 | (d(CH2)51,Tyr(Me)2,Thr4,Orn8,des-Gly-NH29)-Vasotocin, an oxytocin receptor blocker (antagonist), eliminates oxytocin-potentiated inhibitory processes in CA1 pyramidal neurons Aftertouch current. |
|
V74425 | (Val3,Pro8)-Oxytocin | 2134138-89-7 | (Val3,Pro8)-Oxytocin is a Gq-dependent pathway agonist. |
|
V74427 | [Asp5]-Oxytocin | 65907-78-0 | [Asp5]-Oxytocin is a potent 5-position neurohypophyseal hormone analog. |
|
V77767 | [Asp5]-Oxytocin acetate | [Asp5]-Oxytocin acetate is a potent 5-position neurohypophyseal hormone analog. | |
|
V11854 | Atosiban acetate | 914453-95-5 | Atosiban acetate, the acetate salt of Atosiban (RW-22164; Tractocile; RWJ22164), is a novel and potent peptide-based oxytocin and vasopressin antagonist with the potential to be used for spontaneous preterm labor. |
|
V74429 | Barusiban (FE-200440) | 285571-64-4 | Barusiban (FE-200440) is an oxytocin receptor (OT-R) antagonist (Ki=0.8 nM) that can inhibit OT-induced contractions. |
|
V30719 | Carbetocin | 37025-55-1 | Carbetocin is a novel and potent obstetric drug acting as an agonist of the oxytocin receptor (Kiof 7.1 nM) with improved in vivo stability over oxytocin. |
|
V74426 | Carbetocin acetate | 1631754-28-3 | Carbetocin acetate is an oxytocin (OT) analogue and oxytocin receptor agonist/activator with Ki of 7.1 nM. |
|
V74433 | OT antagonist 1 demethyl derivative | 2763705-17-3 | OT antagonist 1 demethyl analogue is the demethylated product of OT antagonist 1. |
|
V81102 | PF-06478939 | PF-06478939 is a non-brain-penetrating peptide that has agonistic effects on oxytocin (OT) receptors and vasopressin receptors with EC50s of 0.01 nM and 0.078 nM, respectively. | |
|
V81103 | PF-06478939 TFA | PF-06478939 (TFA) is a non-brain-penetrating peptide that is an agonist at oxytocin (OT) receptors and vasopressin receptors with EC50s of 0.01 nM and 0.078 nM, respectively. | |
|
V81104 | PF-06655075 TFA | PF-06655075 (TFA) is the TFA form of PF-06655075. | |
|
V74431 | Pro8-Oxytocin | 24327-19-3 | Pro8-Oxytocin is a modified oxytocin (OXT) ligand. |
|
V81200 | Pro8-Oxytocin TFA | Pro8-Oxytocin TFA is a modified oxytocin (OXT) ligand. | |
|
V3619 | Retosiban (GSK 221149; GSK 221149A) | 820957-38-8 | Retosiban(GSK-221149; GSK-221149A)is a novel, potent, orally bioactive, and selective, sub-nanomolar oxytocin receptor antagonist with Ki of 0.65 nM and >1400-fold selectivity over the related vasopressin receptors. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
